QNTM
Quantum BioPharma Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$22M
5Y Perf.-97.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
QNTM vs NRXP vs SAVA vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+645.8%
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+217.3%
QNTM vs NRXP vs SAVA vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | QNTM | NRXP | SAVA | MNMD |
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $22M | $85M | $94M | $2.04B |
| Revenue (TTM) | $0.00 | $242K | $0.00 | $0.00 |
| Net Income (TTM) | $-31M | $-38M | $-106M | $-238M |
| Gross Margin | — | 59.5% | — | — |
| Operating Margin | — | -63.0% | — | — |
| Total Debt | $2M | $631K | $0.00 | $0.00 |
| Cash & Equiv. | $2M | $8M | $129M | $258M |
QNTM vs NRXP vs SAVA vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
QNTM
NRXP
SAVA
MNMD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Quantum BioPharma L… (QNTM) | 100 | 2.5 | -97.5% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
| Cassava Sciences, I… (SAVA) | 100 | 745.8 | +645.8% |
| Mind Medicine (Mind… (MNMD) | 100 | 317.3 | +217.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QNTM vs NRXP vs SAVA vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD leads in 2 of 6 categories, making it the strongest pick for recent price momentum and sentiment and operational efficiency and capital deployment. Quantum BioPharma Ltd. is the stronger pick specifically for capital preservation and lower volatility. NRXP and SAVA also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
QNTM
Quantum BioPharma Ltd.
The Income Pick
QNTM is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.97
- Lower volatility, beta 0.97, Low D/E 36.8%, current ratio 1.07x
- Beta 0.97, current ratio 1.07x
- Beta 0.97 vs SAVA's 1.99
Best for: income & stability and sleep-well-at-night
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader
NRXP is the clearest fit if your priority is growth.
- 101.1% revenue growth vs SAVA's -5.4%
Best for: growth
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA is the clearest fit if your priority is growth exposure.
- EPS growth 77.6%
- 5.4% margin vs NRXP's -157.3%
Best for: growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 5.1% 10Y total return vs SAVA's -19.5%
- +220.3% vs QNTM's -44.2%
- -70.7% ROA vs NRXP's -489.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs NRXP's -157.3% |
| Stability / Safety | QNTM | Beta 0.97 vs SAVA's 1.99 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +220.3% vs QNTM's -44.2% |
| Efficiency (ROA) | MNMD | -70.7% ROA vs NRXP's -489.9% |
QNTM vs NRXP vs SAVA vs MNMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
Segment breakdown not available.
QNTM vs NRXP vs SAVA vs MNMD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGNRXP
Who Leads Where
MNMD leads in 2 of 6 categories
SAVA leads 1 • QNTM leads 0 • NRXP leads 0 • 2 tied
Explore the data ↓NRXPNRx Pharmaceuticals, …
0leads
QNTMQuantum BioPharma Ltd.
0leads
SAVACassava Sciences, Inc.
1leads
MNMDMind Medicine (MindMe…
2leads
6 Total Categories
CATEGORYLEADERvs SAVAvs QNTMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NRXP and MNMD operate at a comparable scale, with $242,000 and $0 in trailing revenue.
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $242,000 | $0 | $0 |
| EBITDAEarnings before interest/tax | -$4M | -$31M | -$110M | -$191M |
| Net IncomeAfter-tax profit | -$31M | -$38M | -$106M | -$238M |
| Free Cash FlowCash after capex | -$6M | -$12M | -$84M | -$174M |
| Gross MarginGross profit ÷ Revenue | — | +59.5% | — | — |
| Operating MarginEBIT ÷ Revenue | — | -63.0% | — | — |
| Net MarginNet income ÷ Revenue | — | -157.3% | — | — |
| FCF MarginFCF ÷ Revenue | — | -49.0% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +60.4% | -80.0% | +62.1% | -163.0% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SAVA and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Market CapShares × price | $22M | $85M | $94M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $22M | $78M | -$34M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -2.30x | -3.76x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 69.60x | — | — |
| Price / BookPrice ÷ Book value/share | 3.15x | — | 0.63x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — SAVA and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-9 for QNTM. On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs QNTM's 1/9, reflecting solid financial health.
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.4% | — | -95.8% | -102.5% |
| ROA (TTM)Return on assets | -2.2% | -4.9% | -75.3% | -70.7% |
| ROICReturn on invested capital | -2.2% | — | -6.3% | -3.9% |
| ROCEReturn on capital employed | -197.0% | — | -99.9% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.37x | — | — | — |
| Net DebtTotal debt minus cash | -$29,093 | -$7M | -$129M | -$258M |
| Cash & Equiv.Liquid assets | $2M | $8M | $129M | $258M |
| Total DebtShort + long-term debt | $2M | $631,000 | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -54.04x | -24.18x | — | -21.81x |
MNMD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,493 today (with dividends reinvested), compared to $96 for NRXP. Over the past 12 months, MNMD leads with a +220.3% total return vs QNTM's -44.2%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs QNTM's -60.5% — a key indicator of consistent wealth creation.
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -30.4% | +17.6% | -6.5% | +51.7% |
| 1-Year ReturnPast 12 months | -44.2% | +50.2% | +15.0% | +220.3% |
| 3-Year ReturnCumulative with dividends | -93.8% | -50.3% | -40.8% | +510.3% |
| 5-Year ReturnCumulative with dividends | -95.2% | -99.0% | -64.6% | -55.1% |
| 10-Year ReturnCumulative with dividends | -99.6% | -96.8% | -19.5% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -60.5% | -20.8% | -16.0% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — QNTM and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
QNTM is the less volatile stock with a 0.97 beta — it tends to amplify market swings less than SAVA's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs QNTM's 12.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 1.89x | 1.99x | 1.63x |
| 52-Week HighHighest price in past year | $38.25 | $3.84 | $4.98 | $21.09 |
| 52-Week LowLowest price in past year | $2.07 | $1.62 | $1.54 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +12.8% | +80.2% | +39.3% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 58.4 | 65.0 | 46.8 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 496K | 924K | 727K | 779K |
Evenly matched — QNTM and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SAVA as "Buy", MNMD as "Buy".
| Metric | QNTMQuantum BioPharma… | NRXPNRx Pharmaceutica… | SAVACassava Sciences,… | MNMDMind Medicine (Mi… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | — | $20.00 |
| # AnalystsCovering analysts | — | — | 12 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SAVA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 2 of 6 categories
Loading custom metrics...
QNTM vs NRXP vs SAVA vs MNMD: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is QNTM or NRXP or SAVA or MNMD a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — QNTM or NRXP or SAVA or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -55. 1%, compared to -99. 0% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus QNTM's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — QNTM or NRXP or SAVA or MNMD?
By beta (market sensitivity over 5 years), Quantum BioPharma Ltd.
(QNTM) is the lower-risk stock at 0. 97β versus Cassava Sciences, Inc. 's 1. 99β — meaning SAVA is approximately 105% more volatile than QNTM relative to the S&P 500.
04Which is growing faster — QNTM or NRXP or SAVA or MNMD?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — QNTM or NRXP or SAVA or MNMD?
Quantum BioPharma Ltd.
(QNTM) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QNTM leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — QNTM or NRXP or SAVA or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is QNTM or NRXP or SAVA or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Quantum BioPharma Ltd.
(QNTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QNTM: -99. 6%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between QNTM and NRXP and SAVA and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.